Vident Advisory, LLC Amylyx Pharmaceuticals, Inc. Transaction History
Vident Advisory, LLC
- $3.62 Trillion
- Q2 2024
A detailed history of Vident Advisory, LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 10,843 shares of AMLX stock, worth $68,636. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,843Holding current value
$68,636% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AMLX
# of Institutions
139Shares Held
46.6MCall Options Held
226KPut Options Held
909K-
Vanguard Group Inc Valley Forge, PA4.22MShares$26.7 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.34MShares$21.1 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$16.9 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.61MShares$16.5 Million0.0% of portfolio
-
Abrdn PLC1.97MShares$12.5 Million0.01% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $371M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...